Document:

Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.6  

 
  WARRANT AMENDING AGREEMENT    
  

    THIS AMENDING AGREEMENT made the 12th day of February, 2001. 

BETWEEN:

PHAGE THERAPEUTICS INTERNATIONAL, INC., a Florida corporation, having a principal place of business located at 19017 120th Avenue NE, Suite 102,
Bothell, Washington 98011 

("Phage"
or the "Company") 

AND: 

INTERWEST TRANSFER AGENCY, INC., a transfer company registered by the Securities and Exchange Commission having a principal place of business located at
1981 East Murray Holladay Road, Suite 100, Salt Lake City, Utah 84117 

(the
"Warrant Agent") 

WHEREAS:

	A.
	On
February 25, 2000, Phage and the Warrant Agent entered into a warrant agreement ("Warrant Agreement") whereby the Warrant Agent has agreed to issue, transfer, exchange and
replace certificates evidencing the warrants to be issued under the Warrant Agreement.

	B.
	The
Company, has issued 1,942,858 Units ("Units") of the total 2,000,000 Unit offering subject to the Warrant Agreement. Each Unit consists of one share of Common Stock of the
Company ("Common Stock") and one share purchase warrant (collectively, the "Warrants"), each Warrant is exercisable to purchase one share of Common Stock for $1.25 per share at any time on or before
the end of one year from the date of acquisition of the Units and thereafter for $2.00 per share at any time on or before the end of two years from the date of acquisition, on the terms and conditions
and subject to adjustment in certain circumstances, all as set forth in the Warrant Agreement. 

NOW
THEREFORE, for valuable consideration and upon the mutual covenants and promises contained herein, the parties hereto agree as follows: 

Introductory section, second paragraph, second sentence  

	1.
	In
the introductory section, second paragraph, second sentence shall be amended to state "Each Unit consists of one share of Common Stock of the Company ("Common Stock") and one
share purchase warrant (collectively, the "Warrants"), each Warrant exercisable to purchase one share of Common Stock for $1.25 per share at any time on or before June 1, 2001 and thereafter
for $2.00 per share at any time on or before the end of June 3, 2002, on the terms and conditions and subject to adjustment in certain circumstances, all as set forth in this Agreement. 

Section 2. Date, Denomination and Execution of Warrant Certificates, second sentence  

	2.
	Section
2. Date, Denomination and Execution of Warrant Certificates, second sentence shall be amended to state "Each Warrant Certificate will entitle the registered holder, subject
to the provisions of this Agreement and of the Warrant Certificate, to purchase, on or before the close of business on June 3, 2002 (the "Expiration Date"), one fully paid and non-assessable
share of Common Stock for each Warrant evidenced by the Warrant Certificate, subject to adjustments as provided in Sections 6, for $1.25 per share at any time on or before June 1, 2001
("One Year 

1

 

Exercise
Price") and thereafter for $2.00 per share at any time on or before the end of June 3, 2002 ("Two Year Exercise Price"). 

Section 23. Notices, First Paragraph  

	3.
	Section
23. Notices, first paragraph shall be amended to state "Notice or demand under this Agreement to be given or made on the Company by the Warrant Agent or by the registered
holder of any Warrant Certificate will be sufficiently given or made if sent by first-class or registered mail, postage prepaid, addressed (until another address is filed in writing by the Company
with the Warrant Agent) as follows: 

	 	 	Phage Therapeutics International Inc.

19017 120th Avenue NE, Suite 102

Bothell, Washington 98011"

General  

	4.
	All
other terms of the Warrant Agreement will remain the same.

	5.
	The
Warrant Agreement remains in full force and effect except as expressly amended by this Warrant Amending Agreement.

	6.
	This
Agreement may be executed in any number of counterparts, each of which will be an original, but the counterparts will together constitute one and the same instrument. 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed, all as of the day and year first above written. 

	PHAGE THERAPEUTICS	 	INTERWEST TRANSFER
	INTERNATIONAL INC.	 	COMPANY, INC.
	

By:                           /s/ Darren
Pylot                          	
 	

By:                           /s/
Unreadable                          
	

Title:	
 	

Title:

2

QuickLinks

WARRANT AMENDING AGREEMENTPrepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.8  

 
 

STOCK PURCHASE AMENDING AGREEMENT    
  

    THIS AGREEMENT dated as of the 22nd day of November, 2000. 

BETWEEN:

    PHAGE THERAPEUTICS INTERNATIONAL, INC., a company incorporated under the laws of Florida, having an office and address at 19017
120th Avenue NE, Suite 102, Bothel, Washington 98011. 

    (the
"Company") 

AND: 

    ROBERT MILLER, a businessman having an address at 1645 South Miami Avenue, Miami, Florida 33129; 

    BOLIVAR LONGINES SA, a company having a registered office at Centro Comerical Naraya, Piso 4 Oficina L-10, Alta Vista,
Puerto Ordaz, Venezuela; 

    RICARDO REQUENA, a businessman having an address at 25 de Mayo 444 Piso 2, 11000 Montevideo, Urguay; 

    CADAQUES SA., a company having an address at Benito Blanco 675, Apt. 401, 11300 Montevideo, Urguay; 

    BLANCO DE LONGO, a businesswoman having an address at Carace 524, Apt. 701, Montevideo, Urguay; 

    STRATTON SA, a company having a registered office at 25 de Mayo 444 Piso 2, 11000 Montevideo, Urguay; 

    GIG LIMITED, a company having a registered office at 105 Marbel Drive, Grand Cayman, BWI. 

    (collectively
the "Purchasers") 

WHEREAS:

	A.
	On
October 23, 2000, the Company and Purchasers entered into a purchase and sale agreement ("Purchase Agreement") whereby the Company has agreed to sell to the Purchasers
2,142,857 units for an aggregate purchaser price of $1,500,000. Each "Unit" will consist of one share of the Company's common stock with a par value of $0.001 per share (the "Common Stock") and one
Common Stock purchase warrant (the "Warrant"). Every one and a half Warrants will entitle the holder to acquire one additional share of Common Stock of Phage at an exercise price of $0.70 per share;

	B.
	The
Purchasers have agreed to invest an additional $1,500,000 into the Company within seven (7) days from the date of filing of the Company's Form 10SB-12g
with the Securities and Exchange Commission. In consideration of this investment, the Company has agreed to issue an additional 2,142,857 Units to the Purchasers.

	C.
	The
 parties have agreed to amend the Purchase Agreement as herein provided. 

1

 

    NOW
THEREFORE, for valuable consideration and upon the mutual covenants and promises contained herein, the parties hereto agree as follows: 

Recitals, Clause C, Additional Purchase Price and Terms of Payment  

	1.
	Clause C,
in the Recitals shall be amended to state "The Purchasers have agreed to invest an additional One Million Five Hundred Thousand Dollars ($1,500,000) in equity into
Phage by January 15, 2001. In consideration of this investment Phage has agreed to issue to the Purchasers an additional 2,142,857 Units." 

Article 1:
  Definitions, Second Closing Date  

	2.
	Article 1,
Definitions, "Second Closing Date" be amended to state "Second Closing Date" means January 15, 2001." 

General  

	3.
	All
other terms of the Purchase Agreement will remain the same.

	4.
	The
Purchase Agreement remains in full force and effect except as expressly amended by this Amending Agreement. 

2

 

    IN
WITNESS WHEREOF the parties hereto have caused this Agreement to be duly executed, all as of the day and year first above written. 

	PHAGE THERAPEUTICS INTERNATIONAL, INC.	 	 
	

/s/ DARREN PYLOT   
	
 	

 
	By: Darren Pylot, President

	 	 

	
PURCHASERS:	
 	

 
	

/s/ ROBERT MILLER   
	
 	

/s/ UNREADABLE   

	Name: Robert Miller	 	Name: Bolivar Longines SA
	

/s/ RICARDO REQUENA   
	
 	

/s/ UNREADABLE   

	Name: Ricardo Requena	 	Name: Cadaques S.A.
	

/s/ BLANCA DE LONGO   
	
 	

/s/ UNREADABLE   

	Name: Blanca de Longo	 	Name: Stratton S.A.
	

/s/ UNREADABLE   
	
 	

 
	Name: GIG Limited	 	 

3

QuickLinks

STOCK PURCHASE AMENDING AGREEMENTPrepared by MERRILL CORPORATION

   Exhibit 10.9  

SECURITIES PURCHASE AMENDING AGREEMENT  

    THIS AGREEMENT dated as of the 1st day of March, 2001. 

BETWEEN: 

PHAGE THERAPEUTICS INTERNATIONAL, INC., a company incorporated under the laws of Florida, having an office and address at 19017 120th Avenue NE,
Suite 102, Bothel, Washington 98011. 

(the
"Company") 

AND:

ROBERT MILLER, a businessman having an address at 1645 South Miami Avenue, Miami, Florida 33129; 

BOLIVAR LONGINES SA, a company having a registered office at Centro Comerical Naraya, Piso 4 Oficina L-10, Alta Vista, Puerto Ordaz, Venezuela; 

RICARDO REQUENA, a businessman having an address at 25 de Mayo 444 Piso 2, 11000 Montevideo, Urguay; 

CADAQUES SA., a company having an address at Benito Blanco 675, Apt. 401, 11300 Montevideo, Urguay; 

BLANCO DE LONGO, a businesswoman having an address at Carace 524, Apt. 701, Montevideo, Urguay; 

STRATTON SA, a company having a registered office at 25 de Mayo 444 Piso 2, 11000 Montevideo, Urguay; 

GIG LIMITED, a company having a registered office at 105 Marbel Drive, Grand Cayman, BWI; 

ALEXANDRA MAZ, a businesswoman having an address at 1645 South Miami Avenue, Miami, Florida 33129 

(collectively
the "Purchasers") 

WHEREAS:

	A.
	On
October 23, 2000, the Company and the purchasers listed on Schedule I, entered into a purchase and sale agreement ("Purchase Agreement") whereby the Company has agreed to
sell to the Purchasers 2,142,857 units for an aggregate purchaser price of $1,500,000. Each "Unit" will consist of one share of the Company's common stock with a par value of $0.001 per share (the
"Common Stock") and one Common Stock purchase warrant (the "Warrant"). Every one and a half Warrants will entitle the holder to acquire one additional share of Common Stock of Phage at an exercise
price of $0.70 per share;

	B.
	The
list of purchasers on Schedule I have agreed to invest an additional $1,500,000 into the Company within seven (7) days from the date of filing of the Company's Form
10SB-12g with the Securities and Exchange Commission. In consideration of this investment, the Company has agreed to issue an additional 2,142,857 Units to the Purchasers.

	C.
	The
parties have agreed to amend the Purchase Agreement as herein provided. 

1

 

    NOW
THEREFORE, for valuable consideration and upon the mutual covenants and promises contained herein, the parties hereto agree as follows: 

First Paragraph  

	1.
	This
first paragraph of the Purchase Agreement shall read "AGREEMENT, dated as of October 23, 2000, between Phage Therapeutics International Inc. ("Phage") a Florida
Corporation and the persons and entities listed on Schedule I ("Schedule of Purchasers for First Closing") and Schedule II ("Schedule of Purchasers Two for Second Closing") attached to this Agreement
(collectively known as the "Purchaser" or "Purchasers"). 

Article 1: Definitions, Purchasers  

	2.
	Article 1,
Definitions, "Purchasers" be amended to state ""Purchasers" means the persons and entities listed on Schedule I "Schedule of Purchasers" for the First Closing and
Schedule II "Schedule of Purchasers Two" for the Second Closing." 

Article II. Purchase and Sale of Securities, 2.1(b)  

	3.
	Article II,
Purchase and Sale of Securities, section 2.1(b) be amended to state "at the Second Closing, Units in the amounts corresponding with the subscription amount
set out opposite each Purchaser's name on Schedule II attached to this Agreement. The aggregate principal amount of all Units being issued at the Second Closing pursuant to this Agreement is One
Million Five Hundred Thousand Dollars ($1,500,000). 

Article VI. Affirmative Covenants, 6.15  

	4.
	Article VI,
Affirmative Covenants, section 6.15 be amended to state "Unit Offering. Subject to the satisfaction of the terms
and conditions of this Agreement, the Purchasers irrevocably agree to invest an additional One Million Five Hundred Thousand Dollars ($1,500,000) in equity into Phage within seven (7) days from
the date Phage files a Form 10SB-12g with the Commission. Phage in consideration of this investment has agreed to issue to the Purchasers 2,142,857 units on receipt of these funds. Each "Initial Unit"
will consist of one share of Phage Common Stock and one common stock purchase warrant (the "Series One Warrant"). For every one and a half Warrants the holder will be entitled to acquire one
additional share of common stock of Phage at an exercise price of $0.70 per share. These Warrants will be exercisable at any time on or before December 31, 2001 and their right of exercise will
be subject to the Purchasers having fully exercised the Warrants received at the Initial Closing. 

General  

	5.
	All
other terms of the Purchase Agreement will remain the same.

	6.
	The
Purchase Agreement remains in full force and effect except as expressly amended by this Amending Agreement. 

    IN
WITNESS WHEREOF the parties hereto have caused this Agreement to be duly executed, all as of the day and year first above written. 

	PHAGE THERAPEUTICS INTERNATIONAL, INC.	 	 
	

/s/ Darren Pylot
	
 	

 
	

By:	
 	

Darren Pylot, President	
 	

 

2

 

PURCHASERS:  

	/s/ Robert Miller
	 	/s/ Unreadable

	Name: Robert Miller	 	Name: Bolivar Longines SA
	

/s/ Ricardo Requena
	
 	

/s/ Unreadable

	Name: Ricardo Requena	 	Name: Cadaques S.A.
	

/s/ Blanca de Longo
	
 	

/s/ Unreadable

	Name: Blanca de Longo	 	Name: Stratton S.A.
	

/s/ Unreadable
	
 	

/s/  

	Name: GIG Limited	 	Alexandra Maz

3

 
SCHEDULE II  

 SCHEDULE OF PURCHASERS  

	Name
	 	Address/Facsimile Number
	 	$ Amount of Subscription

	Robert Miller	 	1645 South Miami Avenue

Miami, FL 33129	 	$	211,000
	Bolivar Longines SA	 	Centro Comercial Naraya

Piso 4 Oficina L-10

Alta Vista, Puerto Ordaz, Venezuela	 	$	280,000
	Ricardo Requena	 	25 de Mayo 444 Piso 2

11000 Montevideo, Uruguay	 	$	539,000
	Cadaques SA	 	Benito Blanco 675, Apt. 401

11300 Montevideo, Uruguay	 	$	125,000
	Stratton SA	 	25 de Mayo 444, Piso 2

11000 Montevideo, Uruguay	 	$	275,000
	Alexandra Maz	 	1645 South Miami Avenue

Miami, FL 33129	 	$	70,000

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}]]